Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China

Fineline Cube Aug 4, 2026
Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Fineline Cube Feb 24, 2026

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its iza‑bren, a first‑in‑class EGFR×HER3 bispecific antibody‑drug...

Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026

The U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the...

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026

Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ: ACLX) for USD 115.00...

Company

Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry

Fineline Cube Feb 24, 2026

Pfizer Inc. (NYSE: PFE) has entered into an exclusive commercialization agreement with Sciwind Biosciences Co., Ltd....

Company

Merck Restructures Human Health into Oncology and Specialty Units – Appoints Oosthuizen and Foard to Lead New Divisions

Fineline Cube Feb 24, 2026

Merck & Co. (MSD, NYSE: MRK) announced a major organizational restructuring of its Human Health division,...

Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category 1 innovative humanized anti‑PD‑L1 monoclonal antibody...

Company Drug

Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy

Fineline Cube Feb 14, 2026

Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved...

Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026

Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding...

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026

Siemens Healthineers AG (ETR: SHL) and Mayo Clinic announced an expansion of their strategic partnership, targeting...

Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026

VivaVision Biotech (Zhejiang) Co., Ltd., an ophthalmology-focused biotech company founded in 2016, has submitted its...

Medical Device

Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY

Fineline Cube Feb 14, 2026

Astellas Pharma Inc. (TYO: 4503) announced that its VENTANA CLDN18 (43-14A) Assay has received approval...

Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026

Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with...

Company Drug

3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Fineline Cube Feb 14, 2026

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), announced that...

Company Drug

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

Fineline Cube Feb 13, 2026

Bio-Thera Solutions Inc. (SHA: 688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its...

Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Fineline Cube Feb 13, 2026

First Imaging, a Nantong-based medical imaging equipment provider, has closed a Series B+ financing round...

Company

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

Fineline Cube Feb 13, 2026

CARsgen Therapeutics Holdings Ltd. (HKG: 2171), a China-based CAR-T cell therapy specialist, announced plans to invest...

Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Fineline Cube Feb 13, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in...

Company Medical Device

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

Fineline Cube Feb 13, 2026

Novocure Ltd. (NASDAQ: NVCR), Zai Lab Ltd.’s (NASDAQ: ZLAB, HKG: 9688) Swiss oncology partner, announced FDA clearance for...

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026

China Medical System Holdings Limited (HKG: 0867) announced a licensing agreement with Teikoku Seiyaku Co., Ltd.,...

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Fineline Cube Feb 13, 2026

Organon & Co. (NYSE: OGN) announced fourth quarter and full-year 2025 financial results, with total revenue...

Posts pagination

1 … 77 78 79 … 702

Recent updates

  • Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches
  • ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation
  • NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics
  • CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China
  • NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches

Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.